Clinical Experience with a First-in-Class ASO Against miR-10b for the Treatment of Metastatic Cancer

Time: 11:00 am
day: Conference Day Two

Details:

  • In early discovery efforts, miRNA-10b was identified as a master regulator of the viability of metastatic tumor cells and we developed a therapeutic strategy based on miR-10b inhibition
  • The specific inhibition of miR-10b was achieved using ASOs delivered to metastatic sites by TransCode’s proprietary delivery system (termed TTX-MC138).
  • On the path to clinical development of TTX-MC138, we received FDA authorization for a now completed Phase 0 and an ongoing Phase 1 clinical trial in patients with advanced metastatic cancer

NEW DATA

Speakers:

Zdravka Medarova
Zdravka Medarova